#SOHO2024: Chronic lymphocytic leukemia and small lymphocytic lymphoma

To update you on the exciting content presented at the Society of Hematologic Oncology (SOHO) 2024 Annual Meeting, we have collated our social media coverage. Catch up with our live social media coverage relating to chronic lymphocytic leukemia and small lymphocytic leukemia below.

CONGRESS | #SOHO2024@Othman_Al_Sawaf, @UKKoeln, discusses clinical implications of using MRD as a surrogate for PFS or OS. While MRD showed moderate-to-weak correlation with OS and strong correlation with PFS on a trial level, he suggests that MRD shouldn’t be used as a primary… pic.twitter.com/gg6QFY602w

— Lymphoma Hub (@lymphomahub) September 10, 2024

CONGRESS | #SOHO2024
Lydia Scarfò, @SanRaffaeleMI, presents an overview of covalent BTKi. Next generation cBTKis, acalabrutinib and zanabrutinib, have improved tolerability profile compared with ibrutinib. In the GIMEMA CLL2121 study in >1200 patients with CLL, 12-m OS was 82.9%… pic.twitter.com/Aerw0HTElA

— Lymphoma Hub (@lymphomahub) September 9, 2024

CONGRESS | #SOHO2024 | POSTER
William G. Wierda @MDAndersonNews presents exploratory analyses from the TRANSCEND CLL 004 trial of liso-cel in pts with R/R CLL/SLL. Baseline characteristics such as low tumor burden & fewer lines of prior systemic therapies were associated with… pic.twitter.com/NQxZiKqLeJ

— Lymphoma Hub (@lymphomahub) September 9, 2024

CONGRESS | #SOHO2024 | POSTER
William G. Wierda @MDAndersonNews shared results of the BRUIN 1/2 trial of pirtobrutinib in R/R CLL/SLL. N=35, 24 mo PFS was 74.7% & 81.8% (IRC & INV assessed, resp); ORR was 91.4% & 94.3% (IRC & INV assessed, resp). Safety profile was similar to… pic.twitter.com/4NrWqOCnwh

— Lymphoma Hub (@lymphomahub) September 9, 2024

CONGRESS | #SOHO2024 | POSTER
Arnon P. Kater @amsterdamumc shared early results of the EPCORE CLL-1 trial of epcortitamab in Richter's transformation (RT). N=38, mFU=12.9 mo, ORR was 53% (60% & 44% in 1L RT & 2L RT, resp), CR rate was 42% (50% & 33% in 1L RT & 2L RT, resp), mOS… pic.twitter.com/MVm3YxZK3D

— Lymphoma Hub (@lymphomahub) September 9, 2024

CONGRESS |#SOHO2024 | POSTER
Santiago Ossorio Prendes at Hospital Universitario Gregorio Marañon, reports 6-year time to next treatment extrapolation curve from the GLOW trial of first-line ibrutinib + venetoclax in elderly/unfit pts with CLL. Projected proportion of patients… pic.twitter.com/XCFoHBt89A

— Lymphoma Hub (@lymphomahub) September 9, 2024

CONGRESS | #SOHO2024
William Wierda, @MDAndersonNews, discusses whether continuous therapy is the best option for high-risk pts with CLL. In pts with del(17p)/TP53 mutations, second generation covalent BTK inhibitors (such as ibrutinib) show median PFS of 6+ years, however, are… pic.twitter.com/vAmatBsYuy

— Lymphoma Hub (@lymphomahub) September 6, 2024

CONGRESS | #SOHO2024
William Wierda, @MDAndersonNews, presents post hoc exploratory analysis results of the phase I/II TRANSCEND CLL 004 study evaluating characteristics associated with response to liso-cel in pts with R/R CLL/SLL (n=87). OR and CR rates did not correlate with… pic.twitter.com/iOwOwwnxA3

— Lymphoma Hub (@lymphomahub) September 6, 2024

CONGRESS | #SOHO24 | POSTER
Jan Burger @MDAndersonNews reports 10-year analysis from RESONATE-2 study. 1L ibrutinib continues to show survival benefit in older adults with CLL/SLL including those with the high risk genomic clinical features. 9 yr PFS & OS were 49.7% & 68.0%; No… pic.twitter.com/C1e6RiBMe6

— Lymphoma Hub (@lymphomahub) September 5, 2024

CONGRESS | #SOHO24 | POSTER
William Wierda @wwierda @MDAndersonNews presented 5.5 yr follow up of the phase II CAPTIVATE study. Fixed-duration ibrutinib+venetoclax treatment shows meaningful benefit in pts with CLL/SLL and high-risk genomic features (del(17p)/mutated TP53,… pic.twitter.com/BLKQz5KAxa

— Lymphoma Hub (@lymphomahub) September 5, 2024

CONGRESS | POSTER | #SOHO2024 |
Tamar Tadmor @TadmorTamar presents the phase III BELLWAVE-011 study which will investigate nemtabrutinib vs ibrutinib or acalabrutinib in pts with treatment-naïve CLL/SLL (N=1,200). Primary objectives are to evaluate ORR and PFS, with secondary… pic.twitter.com/eTapscE0Xf

— Lymphoma Hub (@lymphomahub) September 4, 2024